Antimalarial drug comprising alaremycin or derivative thereof as active ingredient
Provided is a preventive and/or therapeutic agent for malaria, comprising, as an active ingredient, 5-acetamido-4-oxo-5-hexenoic acid (Alaremycin) or a derivative thereof. A preventive and/or therapeutic agent for malaria is used which comprises, as an active ingredient, Alaremycin or a derivative thereof represented by formula (I) (wherein R 1 represents a hydroxy group, an amino group, or a substituted or unsubstituted straight chain or branched alkoxy group or alkylamino group having 1 to 8 carbons; R 2 represents hydrogen, a substituted or unsubstituted straight chain or branched alkyl group having 1 to 8 carbons, or a substituted or unsubstituted aromatic group having 4 to 10 carbons; and R 3 represents hydrogen or a methyl group).
1. A method of treating or preventing malaria in a subject in need thereof, comprising administering to the subject Alaremycin or a derivative thereof represented by Formula (I),
wherein R 1 represents a hydroxy group, an amino group, or a substituted or unsubstituted straight chain or branched alkoxy group or alkylamino group having 1 to 8 carbons; R 2 represents hydrogen, a substituted or unsubstituted straight chain or branched alkyl group having 1 to 8 carbons, or a substituted or unsubstituted aromatic group having 4 to 10 carbons; and R 3 represents hydrogen or a methyl group, or a pharmaceutically acceptable salt thereof, in an amount effective to treat or prevent malaria in the subject.
2. The method according to claim 1 , wherein R 1 represents a hydroxy group; R 2 represents a methyl group; and R 3 represents hydrogen.
3. The method according to claim 1 , wherein R 1 represents a methoxy group; R 2 represents a methyl group; and R 3 represents hydrogen.
4. The method according to claim 1 , wherein R 1 represents an amino group; R 2 represents a methyl group; and R 3 represents hydrogen.
5. The method according to claim 1 , in which the Alaremycin or derivative thereof is administered in a pharmaceutical preparation comprising a pharmaceutically acceptable carrier.
6. A method of treating or preventing malaria in a subject in need thereof, comprising administering to the subject a pharmaceutical preparation comprising Alaremycin or a derivative thereof as active ingredient and a pharmaceutically acceptable carrier, wherein the Alaremycin or a derivative thereof is represented by Formula (I),
wherein R 1 represents a hydroxy group, an amino group, or a substituted or unsubstituted straight chain or branched alkoxy group or alkylamino group having 1 to 8 carbons; R 2 represents hydrogen, a substituted or unsubstituted straight chain or branched alkyl group having 1 to 8 carbons, or a substituted or unsubstituted aromatic group having 4 to 10 carbons; and R 3 represents hydrogen or a methyl group, or a pharmaceutically acceptable salt thereof, and wherein the preparation is administered in an amount effective to treat or prevent malaria in the subject.
7. The method according to claim 6 , wherein R 1 represents a hydroxy group; R 2 represents a methyl group; and R 3 represents hydrogen.
8. The method according to claim 6 , wherein R 1 represents a methoxy group; R 2 represents a methyl group; and R 3 represents hydrogen.
9. The method according to claim 6 , wherein R 1 represents an amino group; R 2 represents a methyl group; and R 3 represents hydrogen.
10. The method according to claim 1 , wherein the Alaremycin or derivative thereof is administered via a route selected from oral, inhalation, or parenteral.
11. The method according to claim 10 , wherein the Alaremycin or derivative thereof is administered in tablet form or by injection.
12. The method according to claim 6 , wherein the preparation is administered via a route selected from oral, inhalation, or parenteral.
13. The method according to claim 12 , wherein the preparation is administered in tablet form or by injection.